Mabel Mardones, MD, discusses how Dato-DXd and sacituzumab govitecan may affect first-line treatment for metastatic triple-negative breast cancer.
Mabel Mardones, MD
Advertisement
Mabel Mardones, MD, is a breast medical oncologist at Rocky Mountain Cancer Centers in Denver, Colorado.
Articles by Mabel Mardones, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Frontline Dato-DXd for Metastatic TNBC Ineligible for Immunotherapy
2
Leveraging AI for Optimal Clinical Trial Design in Oncology
3
Real-World Analysis Supports Rethinking Upfront Dose Intensity of Enfortumab Vedotin in Advanced Urothelial Cancer
4
On World Cancer Day, Northwell Highlights a Blueprint for Consistent, System-Wide Cancer Care
5